Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Announces Two More Medical Device Consent Decrees

This article was originally published in The Gray Sheet

Executive Summary

FDA has already completed three consent decrees blocking sales of medical devices in 2007, with two surfacing last week. The agency has not obtained more than two device-related injunctions in any of the previous six years

You may also be interested in...



Facilities Must Stop Using Custom Ultrasonics' System To Reprocess Duodenoscopes, FDA Warns

The US agency issued a safety communication Aug. 17 advising all health care facilities to stop using Custom Ultrasonics' System 83 Plus automated endoscope reprocessors to reprocess duodenoscopes, although facilities may continue to use the AERs to clean and sterilize other flexible endoscopes.

FDA Orders Custom Ultrasonics To Recall All Endoscope Reprocessors

The rare recall order comes as a result of a consent-decree violation by the company, which supplies endoscope reprocessors to almost 3,000 hospitals nationwide. FDA says Custom Ultrasonics has failed to validate its device designs, among other concerns.

CareFusion Mulls Relaunch Of Alaris SE After FDA Lifts Injunction

CareFusion said it is evaluating a timeline for re-introducing its Alaris SE infusion pump after FDA recently informed the firm it has lifted an injunction barring sales of the devices in the U.S

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024483

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel